In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin
Open Access
- 1 March 1984
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 25 (3) , 377-379
- https://doi.org/10.1128/aac.25.3.377
Abstract
The in vitro susceptibilities of 393 recent clinical isolates to WIN 49375, a new quinolone derivative, were determined and concurrently tested with cefotaxime, tobramycin, and piperacillin. In general, members of the family Enterobacteriaceae were not as susceptible to tobramycin and piperacillin as they were to WIN 49375. Methicillin-resistant and -susceptible Staphylococcus aureus were equally susceptible to WIN 49375.Keywords
This publication has 6 references indexed in Scilit:
- Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strainsAntimicrobial Agents and Chemotherapy, 1983
- Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acidAntimicrobial Agents and Chemotherapy, 1983
- Cefotaxime: A Review of in Vitro Antimicrobial Properties and Spectrum of ActivityClinical Infectious Diseases, 1982
- Clinical efficacy of cefotaxime in serious infectionsAntimicrobial Agents and Chemotherapy, 1982
- In Vitro Studies of Piperacillin, a New Semisynthetic PenicillinAntimicrobial Agents and Chemotherapy, 1978
- Piperacillin, a new penicillin active against many bacteria resistant to other penicillinsAntimicrobial Agents and Chemotherapy, 1978